Ippolito D, et al. - Researchers ascertained if perfusion-CT (p-CT) imaging could depict the inhibition of tumor neoangiogenesis induced by Sorafenib in advanced hepatocellular carcinoma (HCC), as well as whether it could be helpful in predicting survival during treatment. For this investigation, 98 p-CT examinations were performed among 29 cirrhotic patients, with advanced HCC, before and every 2 months after Sorafenib administration, on a 256-slice MDCT scanner. Data reported that quantitative analysis of perfusion parameters, represents prognostic indicators helpful in the assessment of response to anti-angiogenic therapy, allowing for optimization of individualized treatment.